

Amendments to the Claims

Please cancel Claims 1-12 and 21-35 and amend Claims 13, 16 and 17. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

Claims 1-12 (cancelled)

13. (Currently Amended) A method for identifying an agent that regulates MYC-dependent transcriptional regulation of gene expression comprising the steps of:
- obtaining an indicator cell that expresses a non-transmembrane chimeric receptor comprising MYC and a ~~ligand~~ hormone binding domain;
 - contacting the resulting indicator cell with an appropriate ~~ligand~~ hormone in the presence and absence of an agent to be evaluated for its ability to regulate MYC's transcriptional regulation activity;
 - isolating mRNA from a plurality of indicator cells; and
 - comparing the level of gene expression in the indicator cells in the presence or absence of the agent
- such that if the effect of MYC on ~~the expression of the gene~~ expression is enhanced or inhibited in the presence and not the absence of the agent, then the agent regulates MYC-dependent transcriptional regulation of gene expression.
14. (Original) The method of Claim 13, wherein the agent is tested for its ability to inhibit MYC-dependent transcriptional regulation of gene expression.
15. (Original) The method of Claim 13, wherein the agent is tested for its ability to activate MYC-dependent transcriptional regulation of gene expression.
16. (Currently Amended) The method of Claim 13, wherein ~~the gene whose level of gene~~ expression is ~~being~~ evaluated for ~~regulation~~ is one or more genes selected from the group consisting of: AHCY, CCND2, ASS, FKBP52, PBEF, TRAP1, FABP52, G0S2, PPIF, hsRBPB8, fibrillarin, TFRC, CksHs2, SLC16A1, IARS, HLA-DRB1, GRPE-homolog,

GPI, HSPD1, HDGF, SF2, coup transcription factor, RPS11, EIF5A and EIF4 γ , A2M, TPM1, PDGFRA, FN1, CTGF, COL3A1, CDKN1A and a dithiolethione-inducible gene.

17. (Currently Amended) The method of Claim 13, wherein the chimeric receptor comprises MYC and the ~~ligand~~ hormone binding domain of the estrogen receptor and wherein the ~~ligand that induces c-myc~~ hormone is 4-hydroxytamoxifen.
18. (Original) The method of Claim 16, wherein the agent is evaluated in the presence of cycloheximide.
19. (Original) The method of Claim 13, wherein the level of gene expression is determined by hybridization to an oligonucleotide microarray.
20. (Original) The method of Claim 13, wherein the level of gene expression is determined by Northern blot analysis.

Claims 21-35 (cancelled)